NASDAQ:STAB

Statera Biopharma (STAB) Stock Price, News & Analysis

$0.0007
0.00 (0.00%)
(As of 05/17/2024 ET)
Today's Range
$0.0007
$0.0007
50-Day Range
N/A
52-Week Range
$0.00
$0.04
Volume
1,390 shs
Average Volume
10,710 shs
Market Capitalization
$38,262.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
STAB stock logo

About Statera Biopharma Stock (NASDAQ:STAB)

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

STAB Stock Price History

STAB Stock News Headlines

Statera BioPharma Inc Ordinary Shares
AEON Biopharma Inc.
Mereo BioPharma Group PLC ADR (MREO)
ARCA biopharma Inc ABIO
POINT Biopharma Global Inc Ordinary Shares PNT
STAB Statera Biopharma, Inc.
See More Headlines
Receive STAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Statera Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:STAB
Employees
46
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.49 million

Miscellaneous

Free Float
51,656,000
Market Cap
$38,262.00
Optionable
Not Optionable
Beta
0.45
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Michael Kevin Handley (Age 52)
    CEO, President & Chairman of the Board
    Comp: $2.87M
  • Mr. Christopher Zosh (Age 48)
    Executive VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer
  • Dr. Robert W. Buckheit Jr. (Age 64)
    Ph.D., Chief Technology Officer

STAB Stock Analysis - Frequently Asked Questions

How have STAB shares performed in 2024?

Statera Biopharma's stock was trading at $0.0006 at the start of the year. Since then, STAB stock has increased by 16.7% and is now trading at $0.0007.
View the best growth stocks for 2024 here
.

How do I buy shares of Statera Biopharma?

Shares of STAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STAB) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners